ATE405267T1 - Benzoxazine zur vorbeugung oder behandlung der durch morphinderivaten verursachte hyperalgesia - Google Patents

Benzoxazine zur vorbeugung oder behandlung der durch morphinderivaten verursachte hyperalgesia

Info

Publication number
ATE405267T1
ATE405267T1 AT05292822T AT05292822T ATE405267T1 AT E405267 T1 ATE405267 T1 AT E405267T1 AT 05292822 T AT05292822 T AT 05292822T AT 05292822 T AT05292822 T AT 05292822T AT E405267 T1 ATE405267 T1 AT E405267T1
Authority
AT
Austria
Prior art keywords
morphine
analgesic effect
hyper
alkyl
benzoxazine
Prior art date
Application number
AT05292822T
Other languages
English (en)
Inventor
Myriam Tirault
Bertrand Debaene
Guern Marie-Emmanuelle Le
Bernard Hublot
Original Assignee
Biocodex
Univ Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocodex, Univ Poitiers filed Critical Biocodex
Application granted granted Critical
Publication of ATE405267T1 publication Critical patent/ATE405267T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05292822T 2005-01-06 2005-12-30 Benzoxazine zur vorbeugung oder behandlung der durch morphinderivaten verursachte hyperalgesia ATE405267T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0500112A FR2880275B1 (fr) 2005-01-06 2005-01-06 Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques

Publications (1)

Publication Number Publication Date
ATE405267T1 true ATE405267T1 (de) 2008-09-15

Family

ID=34954620

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05292822T ATE405267T1 (de) 2005-01-06 2005-12-30 Benzoxazine zur vorbeugung oder behandlung der durch morphinderivaten verursachte hyperalgesia

Country Status (9)

Country Link
US (1) US20060160789A1 (de)
EP (2) EP1683522B9 (de)
AT (1) ATE405267T1 (de)
DE (1) DE602005009126D1 (de)
DK (1) DK1683522T3 (de)
ES (1) ES2313254T3 (de)
FR (1) FR2880275B1 (de)
PL (1) PL1683522T3 (de)
PT (1) PT1683522E (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093247A1 (en) * 2007-10-03 2009-04-09 Microsoft Corporation WWAN device provisioning using signaling channel
US8949434B2 (en) * 2007-12-17 2015-02-03 Microsoft Corporation Automatically provisioning a WWAN device
JP5792185B2 (ja) 2009-12-15 2015-10-07 ザ・ホスピタル・フォー・シック・チルドレンＴｈｅ Ｈｏｓｐｉｔａｌｆｏｒ Ｓｉｃｋ Ｃｈｉｌｄｒｅｎ 線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
AU2019444894B2 (en) * 2019-05-06 2023-07-13 Chemcom S.A. Malodor counteracting composition and agent and the use thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830803A (en) 1965-05-10 1974-08-20 Riker Laboratories Inc 5-loweralkyl-1-phenyl-1,3,4,6-tetrahydro-5h-benz(f)-2,5-oxazocines and 4-ones

Also Published As

Publication number Publication date
PT1683522E (pt) 2008-11-20
FR2880275A1 (fr) 2006-07-07
US20060160789A1 (en) 2006-07-20
EP1683522B9 (de) 2011-03-09
EP1987833A1 (de) 2008-11-05
DK1683522T3 (da) 2009-01-12
PL1683522T3 (pl) 2009-04-30
EP1683522B1 (de) 2008-08-20
ES2313254T3 (es) 2009-03-01
DE602005009126D1 (de) 2008-10-02
EP1683522A1 (de) 2006-07-26
FR2880275B1 (fr) 2007-04-13

Similar Documents

Publication Publication Date Title
ATE405267T1 (de) Benzoxazine zur vorbeugung oder behandlung der durch morphinderivaten verursachte hyperalgesia
BRPI0308495B8 (pt) composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
WO2006014665A3 (en) Arylpyrrolidine derivatives as nk-1/ssri antagonists
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
DK2522667T3 (da) Morphinanforbindelser
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
BRPI0512058A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
DE602005022572D1 (de) Antagonisten des opioidrezeptors
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
UA99492C2 (ru) Производные 1,3-дигидро-5-изобензофуранкарбонитрила и его фармацевтическая композиция для лечения преждевременной эякуляции
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
DK2076502T3 (da) Substituerede carboxamider som antagonister af gruppe-1 metabotrope receptorer
WO2006014703A3 (en) Homopiperdinine derivatives as nk-1 antagonists
DE602005026965D1 (de) Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete aminomethylsubstituierte bicyclische aromatische verbindungen
PL1805169T3 (pl) Inhibitory receptora histaminowego H3, ich wytwarzanie i zastosowania terapeutyczne

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties